Literature DB >> 23224426

Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.

Charlene S Dezzutti1, Florian Hladik.   

Abstract

The use of human mucosal tissue models is an important tool advancing our understanding of the specific mechanisms of sexual HIV transmission. Despite 30 years of study, major gaps remain, including how HIV-1 transverses the epithelium and the identity of the early immune targets (gate keepers). Because defining HIV-1 transmission in vivo is difficult, mucosal tissue is being used ex vivo to identify key steps in HIV-1 entry and early dissemination. Elucidating early events of HIV-1 infection will help us develop more potent and specific HIV-1 preventatives such as microbicides and vaccines. Mucosal tissue has been incorporated into testing regimens for antiretroviral drugs and monoclonal antibodies. The use of mucosal tissue recapitulates the epithelium and immune cells that would be exposed in vivo to virus and drug. This review will discuss the use of mucosal tissue to better understand HIV-1 pathogenesis and prevention modalities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23224426      PMCID: PMC4242793          DOI: 10.1007/s11904-012-0148-2

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  94 in total

1.  Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Authors:  Phalguni Gupta; Deena Ratner; Ming Ding; Bruce Patterson; Lisa C Rohan; Todd A Reinhart; Velpandi Ayyavoo; Xioli Huang; Dorothy L Patton; Bharat Ramratnam; Alexander M Cole
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

2.  Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli.

Authors:  Akiko Nishibu; Brant R Ward; James V Jester; Hidde L Ploegh; Marianne Boes; Akira Takashima
Journal:  J Invest Dermatol       Date:  2006-04       Impact factor: 8.551

3.  A new classification for HIV-1.

Authors:  E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

4.  Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.

Authors:  Sarah Harman; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates.

Authors:  Y Ganor; Z Zhou; D Tudor; A Schmitt; M-C Vacher-Lavenu; L Gibault; N Thiounn; J Tomasini; J-P Wolf; M Bomsel
Journal:  Mucosal Immunol       Date:  2010-06-23       Impact factor: 7.313

6.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

Review 7.  Early HIV-1 target cells in human vaginal and ectocervical mucosa.

Authors:  Ruizhong Shen; Holly E Richter; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2010-12-01       Impact factor: 3.886

8.  Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.

Authors:  Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

9.  HIV type 1 infection in women: increased transcription of HIV type 1 in ectocervical tissue explants.

Authors:  Susana N Asin; Susan K Eszterhas; Christiane Rollenhagen; Alysha M Heimberg; Alexandra L Howell
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

10.  Semen-derived amyloid fibrils drastically enhance HIV infection.

Authors:  Jan Münch; Elke Rücker; Ludger Ständker; Knut Adermann; Christine Goffinet; Michael Schindler; Steffen Wildum; Raghavan Chinnadurai; Devi Rajan; Anke Specht; Guillermo Giménez-Gallego; Pedro Cuevas Sánchez; Douglas M Fowler; Atanas Koulov; Jeffery W Kelly; Walther Mothes; Jean-Charles Grivel; Leonid Margolis; Oliver T Keppler; Wolf-Georg Forssmann; Frank Kirchhoff
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  17 in total

1.  MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.

Authors:  Patrick Barnable; Giulia Calenda; Thierry Bonnaire; Radhika Menon; Keith Levendosky; Agegnehu Gettie; James Blanchard; Michael L Cooney; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.

Authors:  Louise A Ouattara; Patrick Barnable; Paul Mawson; Samantha Seidor; Thomas M Zydowsky; Larisa Kizima; Aixa Rodriguez; José A Fernández-Romero; Michael L Cooney; Kevin D Roberts; Agegnehu Gettie; James Blanchard; Melissa Robbiani; Natalia Teleshova
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

3.  The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

Authors:  Ian McGowan; Timothy Wilkin; Raphael J Landovitz; Chunyuan Wu; Ying Chen; Mark A Marzinke; Craig W Hendrix; Paul Richardson; Susan H Eshleman; Adriana Andrade; Wairimu Chege; Peter L Anderson; Marybeth McCauley; Jason Farley; Kenneth H Mayer; Peter Anton; Rhonda M Brand; Ross D Cranston; Roy Gulick
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

4.  Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.

Authors:  Charlene S Dezzutti; Sarah Yandura; Lin Wang; Bernard Moncla; Elizabeth A Teeple; Brid Devlin; Jeremy Nuttall; Elizabeth R Brown; Lisa C Rohan
Journal:  Pharm Res       Date:  2015-06-16       Impact factor: 4.200

Review 5.  Pharmacokinetics of antiretrovirals in mucosal tissue.

Authors:  Mackenzie L Cottrell; Nithya Srinivas; Angela D M Kashuba
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-03-22       Impact factor: 4.481

6.  Ex Vivo HIV Infection Model of Cervico-Vaginal and Rectal Tissue.

Authors:  Louise A Ouattara; Nikolas C Vann; Gustavo F Doncel
Journal:  Methods Mol Biol       Date:  2022

7.  The Molecular Characterization of Intestinal Explant HIV Infection Using Polymerase Chain Reaction-Based Techniques.

Authors:  Laura Janocko; Andrew D Althouse; Rhonda M Brand; Ross D Cranston; Ian McGowan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

Review 8.  Antiretroviral pharmacology in mucosal tissues.

Authors:  Corbin G Thompson; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

Review 9.  Role Of Vitamin-D Supplementation In TB/HIV Co-Infected Patients.

Authors:  Birhanu Ayelign; Meseret Workneh; Meseret Derbew Molla; Gashaw Dessie
Journal:  Infect Drug Resist       Date:  2020-01-10       Impact factor: 4.003

10.  An ex vivo Model of HIV-1 Infection in Human Lymphoid Tissue and Cervico-vaginal Tissue.

Authors:  Andrea Introini; Christophe Vanpouille; Jean Charles Grivel; Leonid Margolis
Journal:  Bio Protoc       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.